Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy

被引:8
|
作者
Paduano, Francesco [1 ,2 ,3 ]
Colao, Emma [1 ]
Fabiani, Fernanda [1 ]
Rocca, Valentina [1 ,4 ]
Dinatolo, Francesca [1 ]
Dattola, Adele [1 ]
D'Antona, Lucia [1 ,2 ]
Amato, Rosario [1 ,2 ]
Trapasso, Francesco [1 ,4 ]
Baudi, Francesco [1 ,2 ]
Perrotti, Nicola [1 ,2 ]
Iuliano, Rodolfo [1 ,2 ]
机构
[1] Mater Domini Univ Hosp, Med Genet Unit, I-88100 Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Campus S Venuta, I-88100 Catanzaro, Italy
[3] Tecnol Res Inst & Marrelli Hlth, Stem Cells & Med Genet Units, I-88900 Crotone, Italy
[4] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Campus S Venuta,Viale Europa, I-88100 Catanzaro, Italy
关键词
next-generation sequencing (NGS); hereditary cancer predisposition syndromes (HCPS); breast cancer (BC); genetic testing; pathogenic variants (PVs); breast and ovarian analysis of disease incidence and carrier estimation algorithm (BOADICEA); BREAST-CANCER; SUSCEPTIBILITY GENES; MEDICAL GENETICS; AMERICAN-COLLEGE; BRCA2; MUTATION; VARIANTS; WOMEN; IDENTIFICATION; SPECTRUM; CHEK2;
D O I
10.3390/genes13071286
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Germline pathogenic variants (PVs) in oncogenes and tumour suppressor genes are responsible for 5 to 10% of all diagnosed cancers, which are commonly known as hereditary cancer predisposition syndromes (HCPS). A total of 104 individuals at high risk of HCPS were selected by genetic counselling for genetic testing in the past 2 years. Most of them were subjects having a personal and family history of breast cancer (BC) selected according to current established criteria. Genes analysis involved in HCPS was assessed by next-generation sequencing (NGS) using a custom cancer panel with high- and moderate-risk susceptibility genes. Germline PVs were identified in 17 of 104 individuals (16.3%) analysed, while variants of uncertain significance (VUS) were identified in 21/104 (20.2%) cases. Concerning the germline PVs distribution among the 13 BC individuals with positive findings, 8/13 (61.5%) were in the BRCA1/2 genes, whereas 5/13 (38.4%) were in other high- or moderate-risk genes including PALB2, TP53, ATM and CHEK2. NGS genetic testing showed that 6/13 (46.1%) of the PVs observed in BC patients were detected in triple-negative BC. Interestingly, the likelihood of carrying the PVs in the moderate-to-high-risk genes calculated by the cancer risk model BOADICEA was significantly higher in pathogenic variant carriers than in negative subjects. Collectively, this study shows that multigene panel testing can offer an effective diagnostic approach for patients at high risk of hereditary cancers.
引用
收藏
页数:20
相关论文
共 15 条
  • [1] Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients
    Gomes, Renan
    Spinola, Pricila da Silva
    Brant, Ayslan Castro
    Matta, Bruna Palma
    Nascimento, Caroline Macedo
    de Aquino Paes, Silvia Maria
    Bonvicino, Cibele Rodrigues
    dos Santos, Anna Claudia Evangelista
    Moreira, Miguel Angelo Martins
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 851 - 861
  • [2] Germline Variant Spectrum in Southern Italian High-Risk Hereditary Breast Cancer Patients: Insights from Multi-Gene Panel Testing
    Rocca, Valentina
    Lo Feudo, Elisa
    Dinatolo, Francesca
    Lavano, Serena Marianna
    Bilotta, Anna
    Amato, Rosario
    D'Antona, Lucia
    Trapasso, Francesco
    Baudi, Francesco
    Colao, Emma
    Perrotti, Nicola
    Paduano, Francesco
    Iuliano, Rodolfo
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (11) : 13003 - 13020
  • [3] Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients
    Crawford, Beth
    Adams, Sophie B.
    Sittler, Taylor
    van den Akker, Jeroen
    Chan, Salina
    Leitner, Ofri
    Ryan, Lauren
    Gil, Elad
    van't Veer, Laura
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) : 383 - 390
  • [4] PTEN Germline Mutations in Patients Initially Tested for Other Hereditary Cancer Syndromes: Would Use of Risk Assessment Tools Reduce Genetic Testing?
    Mester, Jessica L.
    Moore, Rebekah A.
    Eng, Charis
    ONCOLOGIST, 2013, 18 (10) : 1083 - 1090
  • [5] Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients
    Beth Crawford
    Sophie B. Adams
    Taylor Sittler
    Jeroen van den Akker
    Salina Chan
    Ofri Leitner
    Lauren Ryan
    Elad Gil
    Laura van ’t Veer
    Breast Cancer Research and Treatment, 2017, 163 : 383 - 390
  • [6] Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy
    Nunziato, Marcella
    Di Maggio, Federica
    Pensabene, Matilde
    Esposito, Maria Valeria
    Starnone, Flavio
    De Angelis, Carmine
    Calabrese, Alessandra
    D'Aiuto, Massimiliano
    Botti, Gerardo
    De Placido, Sabino
    D'Argenio, Valeria
    Salvatore, Francesco
    FRONTIERS IN MEDICINE, 2022, 9
  • [7] BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil
    Mazzonetto, Patricia
    Milanezi, Fernanda
    D'Andrea, Mariana
    Martins, Silvia
    Monfredini, Priscilla M.
    Silva, Juliana dos Santos
    Perrone, Eduardo
    Villela, Darine
    Schnabel, Beatriz
    Nakano, Viviane
    Palmero, Edenir Inez
    Braggio, Esteban
    Cavalcanti, Thereza L.
    Guida, Gustavo
    Migliavacca, Michele P.
    Scapulatempo-Neto, Cristovam
    Zalcberg, Ilana
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 127 - 136
  • [8] Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients
    Renan Gomes
    Pricila da Silva Spinola
    Ayslan Castro Brant
    Bruna Palma Matta
    Caroline Macedo Nascimento
    Silvia Maria de Aquino Paes
    Cibele Rodrigues Bonvicino
    Anna Claudia Evangelista dos Santos
    Miguel Angelo Martins Moreira
    Breast Cancer Research and Treatment, 2021, 185 : 851 - 861
  • [9] BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil
    Patricia Mazzonetto
    Fernanda Milanezi
    Mariana D’Andrea
    Silvia Martins
    Priscilla M. Monfredini
    Juliana dos Santos Silva
    Eduardo Perrone
    Darine Villela
    Beatriz Schnabel
    Viviane Nakano
    Edenir Inez Palmero
    Esteban Braggio
    Thereza L. Cavalcanti
    Gustavo Guida
    Michele P. Migliavacca
    Cristovam Scapulatempo-Neto
    Ilana Zalcberg
    Breast Cancer Research and Treatment, 2023, 199 : 127 - 136
  • [10] Validation of the Methotrexate-First Strategy in Patients With Early, Poor-Prognosis Rheumatoid Arthritis: Results From a Two-Year Randomized, Double-Blind Trial
    O'Dell, James R.
    Curtis, Jeffrey R.
    Mikuls, Ted R.
    Cofield, Stacey S.
    Bridges, S. Louis, Jr.
    Ranganath, Veena K.
    Moreland, Larry W.
    ARTHRITIS AND RHEUMATISM, 2013, 65 (08): : 1985 - 1994